Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-96345 SCHEMBL5419354 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL29386897 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5673687 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL1447963 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5419344 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5378537 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL675160 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL675159 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5419350 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL9743556 | 0.95 | TACR1 (0.90) | TACR1CACNA1FCHRM5CACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214692-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | claimed |
| US-20050085414-A1 | Novel medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | claimed |
| US-20020052351-A1 | Novel medical use for tachykinin antagonists | GLAXO GROUP LIMITED | 2002-05-02 | — | — | US | claimed |
| US-6254585-B1 | Surgical irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS, INC. | 2001-07-03 | — | — | US | claimed |
| EP-0409931-B1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER (US) | 1994-02-16 | — | — | EP | claimed |
| US-5162339-A | Substance P Antagonists, Gastrointestinal and Central Nervous System Disorders, Antiinflammatory Agents, Analgesics | PFIZER INC. (US) | 1992-11-10 | — | — | US | claimed |
| EP-0409931-A1 | QUINUCLIDINE THERAPEUTIC AGENTS. | PFIZER (US) | 1991-01-30 | — | — | EP | claimed |
| WO-1990005525-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | claimed |
| WO-1990005729-A1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | claimed |
| US-20140235597-A1 | Ophthalmologic Irrigation Solutions and Method | OMEROS CORPORATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-7342028-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7214692-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-0409931-B1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER (US) | 1994-02-16 | — | — | EP | disclosed |
| EP-0533280-A1 | Novel medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| US-5162339-A | Substance P Antagonists, Gastrointestinal and Central Nervous System Disorders, Antiinflammatory Agents, Analgesics | PFIZER INC. (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0409931-A1 | QUINUCLIDINE THERAPEUTIC AGENTS. | PFIZER (US) | 1991-01-30 | — | — | EP | disclosed |
| WO-1990005525-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | disclosed |
| WO-1990005729-A1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085414-A1 | Novel medical use for tachykinin antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CACNA1F 633/4885CHRM5 263/4885 |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, TRPV1, VIPR2 | TACR1 101/4885CACNA1F 65/4885CHRM5 622/4885 |
| US-20020052351-A1 | Novel medical use for tachykinin antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CACNA1F 657/4885CHRM5 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.